EULAR (European League
. At the EULAR congress in June, recommendations for management will be presented for hand osteoarthritis, fibromyalgia and systemic lupus erythematosus. In addition, recommendations for conducting clinical trials in systemic lupus erythematosus and systemic vasculitis will be presented. Importantly, EULAR and the American College of Rheumatology are currently developing task forces comprising experts from both organiza tions; these task forces will develop joint recommenda tions in specific areas of rheumatology.
Other prominent activities include the establishment of high-standard networks of Centers of Excellence in rheumatology research, the provision of competitive research grants to collaborative projects in Europe, and the donation of bursaries to visiting research fellows.
EULAR aims to influence political processes to improve the awareness and priority level of rheumatic diseases in Europe. The Alliance Against Arthritis was established in 2004 as a campaigning arm of EULAR. Rheumatic diseases are not an explicit priority in the current research framework program of the European Union. An important step in the right direction was the approval of a written declaration, which was signed by the majority of the members of the European Parliament. This declaration, which was adopted in October 2005, calls on the Commission and Council to prioritize rheumatic diseases in health care and research, and to strengthen disability legislation.
EULAR is also working with the European regional office of the WHO to ensure that rheumatic diseases will be part of both the European Strategy on Noncommunicable Diseases and the future program on counteracting obesity, which is of particular relevance in osteoarthritis.
The next major activity of EULAR is the Annual Congress in Amsterdam, The Netherlands, 21-24 June 2006. Last year's Congress attracted nearly 10,000 participants from 99 countries, with more people than usual from outside Europe, including the US. The number of scientific abstracts submitted this year approached 3,000 (an increase of 20% compared with last year). We are also aware that the latest American College of Rheumatology/Association of Rheumatology Health Professionals Annual Scientific Meeting had a larger attendance than ever.
This worldwide growth in the profile of rheumatology reflects the advances that have been achieved over the past few years, such as improvements in our understanding of pathophysiological processes, and the development of new imaging tools and drugs, and better treatment strategies. These achievements also call for a global strategy, which has to take into account, among other factors, that many patients do not have access to these new opportunities. The increasing international collaboration between rheumatology organization gives hope for progress in global strategies to improve the prevention and treatment of rheumatic diseases.
